Factors Influencing the 3-Year Recurrence of Liver Carcinoma After Surgery

October 20, 2016 updated by: Ruechuta Molek

Objective:

  1. To study the factors that influence the 3- year recurrence of liver carcinoma after surgery
  2. To study the related factors affecting recurrence of liver carcinoma after surgery

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Liver carcinoma including 80% Hepatocellular carcinoma (HCC) and 20% Cholangiocarcinoma (CCA) becomes the leading causes of death in East and South-East Asia. Though hepatectomy is the treatment of choice for early stage cancer, the recurrence has been reported as 30%, 62% and 79% in 1st, 3rd and 5th year respectively. Chulabhorn hospital, a cancer institute established in 2011, has been performing a 3-years retrospective study on the influencing factors and its correlation to liver carcinoma after surgery.

Study Type

Observational

Enrollment (Actual)

67

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

There were 33 and 34 patients underwent liver resection for Hepatocellular carcinoma and Cholangiocarcinoma respectively between February 2010 to December 2013. All patients were staged according to the tumor-node metastasis (TNM) system and appraised by the hospital tumor board conference. After surgery, an attending physician followed up patients by tumor marker and imaging as standard treatment as well as diagnosed its recurrence. In addition, all recurrence cases had standard treatments till the end of life. The survival was classified as the dates between the operation and the death.

Description

Inclusion Criteria:

  • All patients underwent liver resection for Hepatiocellular carcinoma and Cholangiocarcinoma respectively including having pathology results between February 2010 to December 2013. Data was received from Cholabhron Hospital's patient database.

Exclusion Criteria:

  • All patients having no pathology results were not included.
  • All patients having no show for follow up recording were excluded.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
recurrence rate of HCC after surgery
There were 33 for Hepatocellular carcinoma between February 2010 to December 2013. All patients were staged according to the tumor-node metastasis (TNM) system and appraised by the hospital tumor board conference. After surgery, an attending physician followed up patients by tumor marker and imaging as standard treatment as well as diagnosed its recurrence. In addition, all recurrence cases had standard treatments till the end of life. The survival was classified as the dates between the operation and the death.
Other: Recurrence Rate of HCC after surgery
Recurrence Rate of HCC after surgery
recurrence rate of CCA after surgery
There were 34 patients underwent liver resection for Cholangiocarcinoma between February 2010 to December 2013. All patients were staged according to the tumor-node metastasis (TNM) system and appraised by the hospital tumor board conference. After surgery, an attending physician followed up patients by tumor marker and imaging as standard treatment as well as diagnosed its recurrence. In addition, all recurrence cases had standard treatments till the end of life. The survival was classified as the dates between the operation and the death.
Other: Recurrence Rate of CCA after surgery
Recurrence Rate of CCA after surgery

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Recurrence rate of Liver Carcinoma after surgery
Time Frame: 3 years
3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ruechuta Molek

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2016

Primary Completion (Actual)

August 1, 2016

Study Completion (Actual)

September 1, 2016

Study Registration Dates

First Submitted

October 20, 2016

First Submitted That Met QC Criteria

October 20, 2016

First Posted (Estimate)

October 21, 2016

Study Record Updates

Last Update Posted (Estimate)

October 21, 2016

Last Update Submitted That Met QC Criteria

October 20, 2016

Last Verified

October 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 010/2016

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Recurrence

Clinical Trials on Recurrence Rate of HCC after surgery

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe